MetaCap

CeriBell (CBLL) vs Stereotaxis (STXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CeriBell (CBLL) has outperformed Stereotaxis (STXS) over the past year, gaining 79.5% versus a loss of 59.4%. CeriBell is the larger company by market cap ($1.06 billion vs $95.0 million), about 11.2 times the size. CeriBell converts more of its revenue into profit, with a net margin of -60.0% versus -66.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CBLL+79.49%STXS-59.39%
+93%+10%-73%
Nov 21, 20251 yearNov 20, 2026
CBLL+9.56%STXS-52.41%
+64%+1%-63%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CBLL versus STXS key metrics
MetricCBLLSTXS
Share price$27.39$0.9422
Market cap$1.06B$95.03M
1-day change+6.37%-6.71%
YTD return+24.90%-59.03%
1-year return+79.49%-59.39%
5-year return—-84.16%
EPS (TTM)$-1.95$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$89.06M$32.38M
Revenue growth (YoY)+36.09%+20.28%
Net income (latest FY)$-53.41M$-21.64M
Gross margin87.89%52.73%
Operating margin-65.57%-68.30%
Net margin-59.97%-66.85%
52-week high$28.89$2.86
52-week low$14.87$0.80
Distance from 52-week high-5.19%-67.06%
Analyst consensusstrong_buynone
Avg. price target upside+15.26%+218.40%
Average volume452.64K715.12K
Shares outstanding38.84M100.86M
Employees327131
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CeriBell is about 11.2 times larger than Stereotaxis by market value ($1.06B vs $95.03M).
  • CBLL has outperformed STXS by 138.9 percentage points over the past year.
  • CeriBell is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -66.8 cents for Stereotaxis.
  • CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +20.28%).

About CeriBell

CBLL stock →

CeriBell, Inc. operates as a medical technology company in the United States.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees

About Stereotaxis

STXS stock →

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees

CBLL vs STXS FAQ

Which is bigger, CeriBell or Stereotaxis?

CeriBell (CBLL) is larger, with a market capitalization of $1.06B compared with $95.03M for Stereotaxis (STXS).

Which stock has performed better over the past year, CBLL or STXS?

CBLL returned +79.49% over the past 12 months, compared with -59.39% for STXS (price return, excluding dividends). Past performance does not predict future results.

Are CeriBell and Stereotaxis in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons